Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 4/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088528 | 0.89 | NQO2 (0.51) | CA2MEN1MAPTKMT2ANQO2 | |
| SCHEMBL3086379 | 0.88 | CA2 (0.49) | CA2MEN1MAPTKMT2ANQO2 | |
| SCHEMBL3092580 | 0.84 | CA2 (0.50) | CA2MEN1MAPTKMT2AMTNR1A | |
| SCHEMBL3097281 | 0.83 | HTR6 (0.43) | CA2MAPTNQO2CASP6CA12 | |
| SCHEMBL3080740 | 0.82 | CA2 (0.44) | CA2MEN1MAPTKMT2ANQO2 | |
| SCHEMBL14344711 | 0.82 | CA2 (0.48) | CA2MEN1MAPTKMT2ACYP2C9 | |
| SCHEMBL3092172 | 0.81 | NQO2 (0.48) | CA2MEN1MAPTKMT2ANQO2 | |
| SCHEMBL3090844 | 0.81 | NQO2 (0.47) | CA2MEN1MAPTKMT2ANQO2 | |
| SCHEMBL3096948 | 0.79 | HTR6 (0.49) | CA2NQO2MTNR1AMTNR1BNAMPT | |
| SCHEMBL4006731 | 0.78 | KDM4E (0.44) | CA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| CN-101472885-A | Arylsulfonyl naphthalene derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| EP-2041079-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | CA2 4084/4885MEN1 470/4885MAPT 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.